Nuformix Plc (GB:NFX)
LSE:NFX
Want to see GB:NFX full AI Analyst Report?
Top Page
Nuformix Plc
(LSE:NFX)
Select Model
Select Model
Rating:42Neutral
Price Target:
0.16 p
▼(-29.13% Downside)
Action:Reiterated
Date:03/14/26
The score is primarily constrained by weak financial performance (no recent revenue, ongoing losses, and persistent cash burn), partially offset by a low-debt balance sheet. Technicals are modestly negative with the price below key moving averages, and valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Proprietary cocrystal platform
A proprietary cocrystal platform is a durable competitive asset: it enables multiple reformulations across molecules, supports licensing/partnership models, and shortens development risk versus new chemical entities, underpinning recurring R&D and commercial opportunities.
Negative Factors
No recent revenue
Three consecutive years without meaningful revenue indicates a stalled commercialization profile and that core technology has yet to produce sustainable product sales, forcing reliance on development funding and licensing to validate long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cocrystal platform
A proprietary cocrystal platform is a durable competitive asset: it enables multiple reformulations across molecules, supports licensing/partnership models, and shortens development risk versus new chemical entities, underpinning recurring R&D and commercial opportunities.
Read all positive factors
Nuformix Plc (NFX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.44M
Dividend YieldN/A
Average Volume (3M)97.88M
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue GrowthN/A
EPS Growth90.91%
CountryUK
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nuformix Plc Business Overview & Revenue Model
Company Description
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is a...
How the Company Makes Money
null...
Nuformix Plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Mar 2023 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 50.00K | 195.55K |
| Gross Profit | -28.63K | 0.00 | -36.75K | 11.33K | 86.72K |
| EBITDA | -631.94K | -477.19K | -581.90K | -1.23M | -1.28M |
| Net Income | -652.59K | -3.64M | -572.98K | -1.11M | -1.25M |
Balance Sheet | |||||
| Total Assets | 1.02M | 970.54K | 4.42M | 4.98M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 97.55K | 20.21K | 202.55K | 464.10K | 1.67M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 263.92K | 254.97K | 222.99K | 237.86K | 324.62K |
| Stockholders Equity | 754.93K | 715.57K | 4.20M | 4.74M | 5.69M |
Cash Flow | |||||
| Free Cash Flow | -614.61K | -331.88K | -397.49K | -1.35M | -848.83K |
| Operating Cash Flow | -614.61K | -331.88K | -397.49K | -1.35M | -848.22K |
| Investing Cash Flow | 0.00 | 0.00 | 33.33K | 0.00 | 43.72K |
| Financing Cash Flow | 691.95K | 149.54K | 189.79K | 139.98K | 1.93M |
Nuformix Plc Technical Analysis
Negative
0.23
Price Trends
0.19
Negative
0.22
Negative
0.22
Negative
Market Momentum
>-0.01
Positive
44.90
Neutral
15.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NFX, the sentiment is Negative. The current price of 0.23 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.19, and above the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.90 is Neutral, neither overbought nor oversold. The STOCH value of 15.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:NFX.
Nuformix Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.94M | -0.88 | -53.79% | ― | ― | 85.56% | |
46 Neutral | £29.64M | -3.00 | -6634.51% | ― | ― | ― | |
43 Neutral | £5.94M | -2.61 | -2.42% | ― | 102.28% | 95.58% | |
42 Neutral | £4.44M | -1.83 | -153.80% | ― | ― | 90.91% | |
42 Neutral | £4.07M | -0.40 | -115.97% | ― | -87.82% | -704.65% | |
42 Neutral | £45.49M | -1.82 | -3931.14% | ― | ― | -28.29% |
* Healthcare Sector Average
GB:NFX
Nuformix Plc
0.17
0.06
57.41%
GB:TCF
Evgen Pharma
0.23
>-0.01
-4.17%
GB:FUM
Futura Medical
0.70
-7.30
-91.25%
GB:IMM
ImmuPharma
4.75
1.88
65.79%
GB:OPTI
OptiBiotix Health
5.75
-12.50
-68.49%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
669.00
492.50
279.04%
Nuformix Plc Corporate Events
Regulatory Filings and Compliance
Nuformix updates market on enlarged share capital and voting rights
Neutral
Mar 31, 2026
Nuformix plc has updated investors on its total voting rights following the recent issue of new ordinary shares under a placing completed earlier in March. The company’s issued share capital now comprises 2,609,749,903 ordinary shares of 0.0...
Business Operations and StrategyPrivate Placements and Financing
Nuformix Raises £1m to Accelerate NXP002 Fibrosis Programme
Positive
Mar 11, 2026
Nuformix plc has raised £1.0 million via a placing of 500,000,000 new ordinary shares at 0.20 pence each, with the proceeds earmarked primarily to advance its NXP002 inhaled therapy for idiopathic and progressive pulmonary fibrosis and for ge...
Business Operations and StrategyRegulatory Filings and Compliance
Nuformix Wins US Orphan Drug Status for IPF Candidate NXP002
Positive
Mar 10, 2026
Nuformix has secured U.S. Food and Drug Administration Orphan Drug Designation for tranilast lystate, the inhaled active substance in its NXP002 programme targeting idiopathic pulmonary fibrosis, a rare and high-mortality lung disease. The designa...
Business Operations and StrategyStock BuybackShareholder Meetings
Nuformix Wins Strong Shareholder Backing as All AGM Resolutions Pass
Positive
Mar 3, 2026
Nuformix plc reported that all resolutions at its Annual General Meeting were passed by shareholders, confirming strong support for the company’s strategy and governance. Investors approved the annual report and remuneration, reappointed thr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.